BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 27570979)

  • 1. Perceived barriers to treatment predict adherence to aromatase inhibitors among breast cancer survivors.
    Brier MJ; Chambless DL; Gross R; Chen J; Mao JJ
    Cancer; 2017 Jan; 123(1):169-176. PubMed ID: 27570979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ageing perceptions and non-adherence to aromatase inhibitors among breast cancer survivors.
    Brier MJ; Chambless DL; Chen J; Mao JJ
    Eur J Cancer; 2018 Mar; 91():145-152. PubMed ID: 29329697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying socio-demographic and clinical characteristics associated with medication beliefs about aromatase inhibitors among postmenopausal women with breast cancer.
    Salgado TM; Davis EJ; Farris KB; Fawaz S; Batra P; Henry NL
    Breast Cancer Res Treat; 2017 Jun; 163(2):311-319. PubMed ID: 28251384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between self-report adherence measures and oestrogen suppression among breast cancer survivors on aromatase inhibitors.
    Brier MJ; Chambless D; Gross R; Su HI; DeMichele A; Mao JJ
    Eur J Cancer; 2015 Sep; 51(14):1890-6. PubMed ID: 26169018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of a web-based app to improve breast cancer symptom management and adherence for aromatase inhibitors: a randomized controlled feasibility trial.
    Graetz I; McKillop CN; Stepanski E; Vidal GA; Anderson JN; Schwartzberg LS
    J Cancer Surviv; 2018 Aug; 12(4):431-440. PubMed ID: 29492753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-reported Adherence to Adjuvant Aromatase Inhibitor Therapy Using the Morisky Medication Adherence Scale: An Evaluation of Predictors.
    Kesmodel SB; Goloubeva OG; Rosenblatt PY; Heiss B; Bellavance EC; Chumsri S; Bao T; Thompson J; Nightingale G; Tait NS; Nichols EM; Feigenberg SJ; Tkaczuk KH
    Am J Clin Oncol; 2018 May; 41(5):508-512. PubMed ID: 27322700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Barriers to and facilitative processes of endocrine therapy adherence among women with breast cancer.
    Bright EE; Petrie KJ; Partridge AH; Stanton AL
    Breast Cancer Res Treat; 2016 Jul; 158(2):243-51. PubMed ID: 27342455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving Adherence to Endocrine Therapy in Women With HR-Positive Breast Cancer.
    Brockway JP; Shapiro CL
    Oncology (Williston Park); 2018 May; 32(5):235-7, 249. PubMed ID: 29847854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer.
    Sedjo RL; Devine S
    Breast Cancer Res Treat; 2011 Jan; 125(1):191-200. PubMed ID: 20495864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence to Adjuvant Aromatase Inhibitor Therapy Among Postmenopausal Hispanic/Latino Women With Breast Cancer.
    Philipovskiy A; Campbell A; Heydarian R; Castillo B; Dwivedi AK; McCallum R; Aguilera R; Gaur S; Nahleh Z
    Anticancer Res; 2020 Feb; 40(2):857-864. PubMed ID: 32014929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors.
    Chim K; Xie SX; Stricker CT; Li QS; Gross R; Farrar JT; DeMichele A; Mao JJ
    BMC Cancer; 2013 Sep; 13():401. PubMed ID: 24004677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrine Therapy Nonadherence and Discontinuation in Black and White Women.
    Wheeler SB; Spencer J; Pinheiro LC; Murphy CC; Earp JA; Carey L; Olshan A; Tse CK; Bell ME; Weinberger M; Reeder-Hayes KE
    J Natl Cancer Inst; 2019 May; 111(5):498-508. PubMed ID: 30239824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-Reported Outcomes and Long-Term Nonadherence to Aromatase Inhibitors.
    Hershman DL; Neugut AI; Moseley A; Arnold KB; Gralow JR; Henry NL; Hillyer GC; Ramsey SD; Unger JM
    J Natl Cancer Inst; 2021 Aug; 113(8):989-996. PubMed ID: 33629114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: first-year results from the compliance of aromatase inhibitors assessment in daily practice through educational approach (CARIATIDE) study.
    Neven P; Markopoulos C; Tanner M; Marty M; Kreienberg R; Atkins L; Franquet A; Gnant M; Neciosup S; Tesarova P; Barni S; Deschamp V
    Breast; 2014 Aug; 23(4):393-9. PubMed ID: 24675394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interventions to improve endocrine therapy adherence in breast cancer survivors: what is the evidence?
    Ekinci E; Nathoo S; Korattyil T; Vadhariya A; Zaghloul HA; Niravath PA; Abughosh SM; Trivedi MV
    J Cancer Surviv; 2018 Jun; 12(3):348-356. PubMed ID: 29396760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI.
    Lintermans A; Van Asten K; Wildiers H; Laenen A; Paridaens R; Weltens C; Verhaeghe J; Vanderschueren D; Smeets A; Van Limbergen E; Leunen K; Christiaens MR; Neven P
    Breast Cancer Res Treat; 2014 Jul; 146(1):109-16. PubMed ID: 24816806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence to Adjuvant Endocrine Therapy in Women With Breast Cancer: A Prospective Observational Study in Japanese Women.
    Kuba S; Maeda S; Matsumoto M; Yamanouchi K; Yano H; Morita M; Sakimura C; Hatachi T; Tokai Y; Takatsuki M; Fujioka H; Hayashida N; Nagayasu T; Eguchi S
    Clin Breast Cancer; 2018 Apr; 18(2):150-156. PubMed ID: 29290564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence to adjuvant endocrine therapy in postmenopausal breast cancer patients: A 5-year prospective study.
    Hagen KB; Aas T; Kvaløy JT; Søiland H; Lind R
    Breast; 2019 Apr; 44():52-58. PubMed ID: 30641300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence to long-term adjuvant hormonal therapy for breast cancer.
    Gotay C; Dunn J
    Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):709-15. PubMed ID: 22098287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy.
    Kimmick G; Edmond SN; Bosworth HB; Peppercorn J; Marcom PK; Blackwell K; Keefe FJ; Shelby RA
    Breast; 2015 Oct; 24(5):630-6. PubMed ID: 26189978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.